MedTrace Logo

Ocular Allergy Treatment Practical Impact Trial

NCT01808768 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2013-05-30

No results posted yet for this study

Summary

To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.

Conditions

  • Allergic Conjunctivitis
  • Rhinoconjunctivitis

Interventions

DRUG

Alcaftadine

Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.

Sponsors & Collaborators

  • Starx Research Center, LLC

    lead INDUSTRY

Principal Investigators

  • Jayesh Kanuga, MD · Starx Research Center, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-10-31
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01808768 on ClinicalTrials.gov